Antimicrobials for global health and addressing unmet medical needs

Led by Professor William Hope OBE, the focus of the group is the development of new therapeutic approaches to urgent threats posed by AMR using state-of-the-art pharmacodynamic and pharmacometric tools.

Our research

• Development of new treatments for fungal diseases such as cryptococcal meningitis and Candida, in collaboration with Queen's University Belfast and MRC Centre for Medical Mycology at the University of Exeter.
• Understanding resistance liabilities of compounds listed in the WHO Essential Medicines List, in collaboration with CAMO-Net.
• Development of antimicrobial combinations for global cefiderocol based regimens, in collaboration with the Global Antibiotic Research & Development Partnership (GARDP)
• New treatments for neonatal sepsis, in collaboration with the Global Antibiotic Research & Development Partnership (GARDP)
• Development of new experimental platforms for MDR/XDR pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa, in collaboration with iiCON